Archives for March 2025

ASE Recognizes Record Number of 2025 Industry Roundtable Partners

FOR IMMEDIATE RELEASE

Contact: Natalie Costantino
919-297-7170
NCostantino@ASEcho.org  

American Society of Echocardiography Recognizes
Record Number of 2025 Industry Roundtable Partners

(DURHAM, NC, March 13, 2025)—The American Society of Echocardiography (ASE) is proud to announce its 2025 Industry Roundtable (IRT) Partners—the largest group in the program’s history, with 23 companies joining this vital collaboration. This milestone comes as ASE celebrates its 50th Anniversary and continues to advance the future of cardiovascular ultrasound through innovation, education and industry partnerships.

The ASE IRT program fosters collaboration between industry leaders, practitioners, and scientists with the shared goal of enhancing patient care by improving cardiovascular ultrasound imaging quality. These partnerships play a crucial role in driving research, shaping clinical guidelines and accelerating the adoption of emerging technologies.

From March 14-16, 2025, the 2025 IRT Partners will convene in New York City for the annual ASE Industry Think Tank, an exclusive forum for discussing key trends impacting clinical practice and industry innovation. This year’s Think Tank explores critical topics, such as emerging technologies, workforce challenges, and evolving care models, ensuring cardiovascular ultrasound remains at the forefront of patient care.

2025 ASE IRT Partners:

  • Abbott
  • Alnylam
  • AstraZeneca
  • Bracco
  • BridgeBio
  • Bristol Myers Squibb
  • Cytokinetics
  • EchoIQ
  • Edwards Lifesciences
  • Edwards Lifesciences TMTT
  • Edwards Lifesciences Surgical Division
  • Fujifilm Healthcare Americas Corp. (Cardiovascular Ultrasound)
  • Fujifilm Healthcare Americas Corp. (Medical Informatics)
  • GE HealthCare
    (Cardiovascular Ultrasound)
  • GE HealthCare
    (Pharmaceutical Diagnostics)
  • Intel
  • JenaValve
  • Lantheus
  • Pfizer
  • Philips Healthcare
  • Siemens Healthineers
  • Ultromics
  • Visura Technologies

“The ASE IRT Partners are instrumental in shaping the future of cardiovascular ultrasound,” said Linda Gillam, MD, MPH, FASE, chair of the ASE Industry Relations Committee. “Their collaboration drives innovation, improves clinical standards and ultimately enhances patient outcomes. As ASE celebrates its golden anniversary, we recognize the contributions of our industry partners in advancing the field and ensuring its continued impact on cardiovascular care.”

For more information about ASE’s IRT Program, visit ASEcho.org/IRT.

About American Society of Echocardiography
The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals™. ASE is the largest global organization for cardiovascular ultrasound imaging serving physicians, sonographers, nurses, veterinarians, and scientists and as such is the leader and advocate, setting practice standards and guidelines for the field. The Society is committed to advancing cardiovascular ultrasound to improve lives. In 2025, ASE is celebrating its milestone 50th anniversary.  For more information, visit the ASE website ASEcho.org or social media pages on Facebook, X, LinkedIn, Instagram and Bluesky.

 

###

ASE Announces Accelerator Program

FOR IMMEDIATE RELEASE

Contact: Natalie Costantino
919-297-7170
NCostantino@ASEcho.org  

American Society of Echocardiography Announces
Accelerator Program to Drive Discovery Through Connection

(DURHAM, NC, March 12, 2025)—The American Society of Echocardiography (ASE) is proud to announce the launch of the ASE Accelerator Program, an initiative designed to support breakthroughs in the field of cardiovascular ultrasound. This innovative program provides participants with early and ongoing product development feedback, access to research validation opportunities, regulatory guidance and strategies for market commercialization.

The ASE Accelerator Program is designed for early-stage companies developing technologies that enhance echocardiographic imaging, streamline workflows and ultimately improve patient outcomes. Whether through AI-driven diagnostics, cutting-edge robotics, or portable imaging solutions, startups selected for the program gain access to ASE’s network, fostering collaborations that might otherwise take years to develop. ASE is pleased to introduce UltraSight™, a company transforming cardiac clinical workflows through machine learning by empowering minimally trained clinicians to capture high quality cardiac ultrasound images in any care setting, as the first ASE Accelerator Partner, marking a significant milestone in this new initiative.

“Innovation in healthcare technology is often driven by startups—lean, agile, and unafraid to challenge the status quo. However, these young companies frequently face significant hurdles, including regulatory challenges, funding limitations, and access to clinical data for validation,” said ASE Board of Directors President Theodore Abraham, MD, FASE. “The ASE Accelerator Program provides a lifeline to these promising ventures, offering mentorship, market fit validation, possible industry partnerships, and the opportunity to engage with key opinion leaders who can help refine their solutions. As the world’s largest cardiac subspecialty organization, an ASE partnership carries immense value. UltraSight is the perfect organization to be ASE’s first Accelerator Partner.”

For UltraSight, participation in the ASE Accelerator Program presents a pivotal opportunity. Andrew Goldsmith, MD, MBA, Medical Director at UltraSight shared, “UltraSight is revolutionizing cardiac care by empowering any healthcare professional to capture diagnostic-quality cardiac images at the bedside. This addresses critical limitations in access to cardiac imaging by providing reliable and predictable image capture that integrates efficiently within existing clinical workflows. Participation in the ASE Accelerator Program, as the first participant, presents a significant opportunity to contribute to evidence-based decision-making in cardiac care. This collaboration with leading experts will enable us to optimize the implementation of this technology and improve patient access to essential cardiac diagnostics.” 

ASE looks forward to welcoming additional Accelerator Partners in the future and driving advancements that will shape the next generation of cardiovascular ultrasound technology. In alignment with this commitment, ASE’s 2025 Scientific Sessions in Nashville, Tenn., will feature a special “Shark Tank” session on Saturday, September 6, to connect innovators with key stakeholders and showcase groundbreaking ideas and cutting-edge advancements in cardiovascular ultrasound. 

Learn more about ASE’s Accelerator Program at ASEcho.org/AcceleratorProgram.

 

About American Society of Echocardiography
The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals™. ASE is the largest global organization for cardiovascular ultrasound imaging serving physicians, sonographers, nurses, veterinarians, and scientists and as such is the leader and advocate, setting practice standards and guidelines for the field. The Society is committed to advancing cardiovascular ultrasound to improve lives. In 2025, ASE is celebrating its milestone 50th anniversary.  For more information, visit the ASE website
ASEcho.org or social media pages on Facebook, X, LinkedIn, Instagram and Bluesky.

 

###

ASE Requests Public Comment on Upcoming Guideline

An upcoming ASE guideline is accepting public comments regarding the, “Guidelines for the Standardization of Adult Echocardiographic Reporting: Recommendations for the American Society of Echocardiography” (Scroll down to view the guideline draft). This document provides an update to the previously published 2002 guideline on the required components for a comprehensive echocardiography report. Once the guideline is completed, it will be published in the Journal of the American Society of Echocardiography.

Guideline Overview:
This document (Scroll down to view the guideline draft) focuses on the final phases of the imaging life cycle, specifically reporting and communicating exam results. Additionally, this guideline delineates core measurements and statements applicable to transthoracic, transesophageal, and stress echocardiography. It also elucidates abbreviations, acronyms, terminology, and definitions to enhance communication across various echocardiography (echo) labs, institutions, and healthcare systems.

Public Comment Purpose:
The aim of the public comment period is to offer involvement and engagement in the guideline development process. This will help ensure that our guideline recommendations provides comprehensive standardization of adult echocardiographic reporting.

Rationale:
The authors and The American Society Echocardiography (ASE) seek feedback from our constituents to gain impartial input regarding key recommendations.

Disclaimer: All documents and materials produced by ASE are protected under intellectual property rights. Unauthorized distribution, duplication, or use of any such materials is strictly prohibited.

The manuscript and tables are Copyright ©️ 2025 American Society of Echocardiography. All Rights Reserved.

 

Public Comment Form

 

Instructions for Submitting Comments:

    • Deadline: All comments must be received by March 31, 2025. Comments received after March 31st will not be accepted.
    • Anonymity: All comments received will remain anonymous.
    • Do not distribute or publish: This guideline is confidential and embargoed until publication.
    • Eligibility: ASE Members, Members of Collaborating Societies, and Industry Partners
    • Format: Limit responses to 250 characters per question
    • Submission Methods:
      • Comments may be submitted electronically ONLY through this Public Comment Form.
      • Comments will not be accepted by email.
      • You will not receive a response to your comments.
      • Comments received by March 31st will be carefully considered, however, there is no guarantee that comments will be included in the guideline.
    • Content:
      • This document is a DRAFT. Please refrain from grammatical and/or editorial comments.
      • Do not leave any questions blank. Insert ‘N/A’ if you choose not to answer a question.
      • Be respectful and constructive in your responses.
      • Focus on the specific issues.
      • Provide any supporting information (e.g., scholarly literature) that can help us understand your perspective.
    • Confidentiality: We reserve the right to make comments public, therefore, refrain from including personal or classified information.
    • Citations: Comments that include non-scholarly or unpublished documents will not be accepted.
    • Submission: Click the ‘Submit’ button at the bottom of the form once you have completed the questionnaire.

 

Draft to Review:Adult Echo Reporting Standard GL_Public Comment

 

Tables referenced in Draft:

Adult Echo Reporting Standard GL Tables_Public Comment

 

Public Comment Form

ASE thanks you for your participation!

NOTE: If you have trouble responding to the public comment form please email Guidelines@ASEcho.org.

ASE Releases New Guideline: Right Heart in Adults & Pulmonary Hypertension

FOR IMMEDIATE RELEASE

Contact: Natalie Costantino
919-297-7170
NCostantino@ASEcho.org

ASE Releases New Guidelines on Echocardiographic Assessment of the Right Heart in Adults

(DURHAM, NC, March 6, 2025)—A new guideline from the American Society of Echocardiography (ASE) offers updated recommendations for clinicians evaluating right heart function in patients with pulmonary hypertension (PH), a condition that significantly affects patient outcomes, morbidity, and mortality.

Guidelines for Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography is published in the March 2025 Journal of the American Society of Echocardiography and supersedes ASE’s right heart guideline published in 2010. This new document emphasizes the critical importance of accurate right heart assessment in the management of PH, which is a key factor in determining clinical prognosis and guiding treatment strategies.

The guideline’s Chair Dr. Monica Mukherjee, who is a cardiologist and the Medical Director of Johns Hopkins Bayview Echocardiography Lab in Baltimore, Md., said this document represents a crucial step forward in the echocardiographic assessment of the right heart in PH. It ensures clinicians and sonographers have the most precise and validated parameters to improve screening and early detection in patients.

“These guidelines have the potential to significantly impact patient care by standardizing and refining echocardiographic assessment of the right heart by focusing on screening and early detection, and improved risk stratification and monitoring of therapeutic response,” said Dr. Mukherjee. “By integrating comprehensive echocardiography techniques and employing updated diagnostic thresholds, we hope to enhance the accuracy of PH evaluation and ultimately guide more precise therapeutic decisions to improve patient outcomes.”

The World Symposium on Pulmonary Hypertension recently redefined PH as a mean pulmonary arterial pressure >20 mmHg, based on epidemiologic evidence highlighting the significant impact of even mildly elevated mean pulmonary artery pressure on morbidity and mortality. The implementation of these new standards will enhance clinical decision-making and foster greater consistency in clinical research applications.

An international multidisciplinary team assisted in developing the guidelines, including expert sonographers and other leading authorities in echocardiography, multimodality imaging, cardiology and PH. The writing group brings expertise in right heart physiology and pulmonary vascular disease, and defines key imaging metrics. This ensures that the document is comprehensive, evidence-based, and clinically impactful.

“By leveraging our collaborative expertise across these specialties, we hoped to provide a unified, physiologically informed framework for assessing right heart function and refining risk stratification based on reproducible echocardiographic parameters that align with disease pathophysiology,” said Guideline Co-Chair, Dr. Lawrence Rudski, the Director of the Azrieli Heart Centre at Jewish General Hospital and Professor of Medicine at McGill University in Montreal, Quebec, Canada.

The complete guideline document and all guidelines published by ASE are available at ASEcho.org/Guidelines.

About American Society of Echocardiography
The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals™. ASE is the largest global organization for cardiovascular ultrasound imaging serving physicians, sonographers, nurses, veterinarians, and scientists and as such is the leader and advocate, setting practice standards and guidelines for the field. The Society is committed to advancing cardiovascular ultrasound to improve lives. In 2025, ASE is celebrating its milestone 50th anniversary.  For more information, visit the ASE website ASEcho.org or social media pages on Facebook, X, LinkedIn, Instagram and Bluesky.

###

Marching On to the Beat: A JASE Focus Issue

The March issue of JASE is entirely focused on the echocardiographic assessment of the right heart. It includes a new Society guideline, “Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography.” The writing group was led by Drs. Monica Mukherjee and Lawrence Rudski.

This issue’s original investigations incorporate a variety of topics including length indexing for right ventricular function, tricuspid regurgitation, exercise echocardiography, and sex differences in right heart size in pulmonary hypertension. Regarding his original investigation, “Association With Outcomes of Correcting the Proximal Isovelocity Surface Area Method to Quantitate Secondary Tricuspid Regurgitation,” lead author Michele Tomaselli, MD, remarks, “The PISA method, when adjusted for the leaflets of the tricuspid valve and the low velocities of the regurgitant jet, improves its overall accuracy and prediction of outcomes, particularly in cases of ventricular secondary tricuspid regurgitation.” Editorial comments accompany three of these original investigations, addressing proximal isovelocity surface area correction in tricuspid regurgitation, atrial secondary tricuspid regurgitation, and assessment of RV function in patients with and without tricuspid regurgitation. Two brief research communications discuss prognostic value of right ventricular dysfunction in dilated cardiomyopathy and quantification of lung perfusion by a novel echocardiographic approach in pediatric pulmonary vein stenosis. Rounding out this issue is a letter to the editor about artificial intelligence-based detection of tent-like signs in intracardiac echocardiography to assist transseptal puncture.

Guest written by Susan E. Wiegers, MD, FASE, this month’s President’s Message honors the beautiful life and legacy of James N. Kirkpatrick, MD, FASE.

A new call for papers is now open! A focus issue on chamber quantification is set for publication in early 2026. Papers that address any aspect of echocardiography in quantitative assessment of the cardiac chambers should be submitted by June 1, 2025. Please direct questions to JASE managing editor Debbie Meyer at dmeyer@asecho.org.

Tune into our Author Spotlight page for interviews between JASE Editor-in-Chief Patricia Pellikka, MD, FASE, and authors of recently published papers. February’s interview features Kevin M. Harris, MD, FASE, discussing his paper, “Rate of Ascending Aortic Enlargement in a Large Echocardiographic Cohort: Associated Risk Factors and Adverse Aortic Events.”
Please see the March ASE Education Calendar for a listing of educational opportunities far and wide

Apply for Co-Director of Echo Hawaii or Co-Chair Positions for ASE’s Virtual Courses

Application Deadline: March 24, 2025 

Along with Course Directors and Chairs, Course Co-Directors and Co-Chairs are instrumental in the implementation and success of live and virtual courses. All applications for available positions can be submitted now through March 24th. The ASE Education Committee will review applications and make recommendations to the ASE Executive Committee, who will make the final selection on April 8th.

 

ASE Course Co-Director Positions

It is current policy that the Co-Director becomes the Course Director after two years and will then serve as the Course Director for two years. The application process for Course Co-Director beginning in 2027 and serving through 2028 is now open for the following ASE courses:

 

ASE Virtual Co-Chair Positions

It is current policy that the Co-Chair becomes the Course Chair after one year, and then will serve as the Course Chair for one year. The application process for Course Co-Chair for 2027 is now open for the following ASE courses:

NOTE: Since the chair and co-chair for the PCHD are required to be a physician and a sonographer, the 2027 PCHD Co-Chair must be a sonographer.